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Combination of erythropoietin and sildenafil can effectively
attenuate hypoxia-induced pulmonary hypertension in mice
Victor Samillan,1,2,3 Thomas Haider,1,2 Johannes Vogel,1,2 Caroline Leuenberger,1,4
Matthias Brock,1,5 Colin Schwarzwald,6 Max Gassmann,1,2,7 Louise Østergaard1,2
1Institute for Veterinary Physiology, Vetsuisse Faculty, Zurich, Switzerland; 2Zurich Center for Integrative Human Physiology, Zurich,
Switzerland; 3Human Physiology Department, Medical School, Universidad Alas Peruanas, Lima, Peru; 4Institute of Human Movement
Sciences and Sport, ETH Zurich, Zurich, Switzerland; 5Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland;
6Equine Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; 7Universidad Peruana Cayetano Heredia, Lima, Peru
Abstract: Pulmonary hypertension (PH) is an incurable disease that often leads to right ventricular hyper-
trophy and right heart failure. This study investigated single versus combined therapy with sildenafil and
erythropoietin on hypoxia-induced pulmonary hypertension in mice. Mice were randomized into 5 groups
and exposed to either hypoxia (10% oxygen) or normoxia for a total of 5 weeks. Hypoxic mice were treated
with saline solution, erythropoietin (500 IU/kg 3 times weekly), sildenafil (10 mg/kg daily), or a combina-
tion of the two drugs for the last 2 weeks of hypoxic exposure. We measured right ventricular pressures
using right heart catheterization, and the ventilatory response to hypoxia was recorded via whole-body ple-
thysmography. Histological analyses were performed to elucidate changes in pulmonary morphology and
appearance of right heart hypertrophy. Plasma levels of cardiotrophin-1 and atrial natriuretic peptide were
quantified. Treatment with either erythropoietin or sildenafil alone lowered the hypoxia-induced increase
of pulmonary pressure and reduced pulmonary edema formation, pulmonary vascular remodeling, and
right ventricular hypertrophy. Notably, the combination of the two drugs had the most prominent effect.
Changes in cardiotrophin-1 and atrial natriuretic protein levels confirmed these observations. The combi-
nation treatment with erythropoietin and sildenafil demonstrated an attenuation of the development of
hypoxia-induced PH in mice that was superior to that observed for either drug when given alone.
Keywords: edema, pulmonary remodeling, right ventricular hypertrophy.
Pulm Circ 2013;3(4):898-907. DOI: 10.1086/674758.
INTRODUCTION
Exposure to chronic hypoxia occurs not only in high-
altitude residents but also in patients suffering from chronic
diseases associated with a reduced oxygen transport ca-
pacity during wakefulness and/or sleep, such as chronic
heart failure, chronic obstructive pulmonary disease, and
sleep apnea.1-4 A frequently observed comorbidity in these
patients is pulmonary hypertension (PH), a progressive
and so far incurable chronic disease characterized by in-
creased pulmonary vascular resistance, high pulmonary
pressure, and remodeling of the pulmonary vessels.5 Al-
though PH is a disease of various origins,6,7 chronic hyp-
oxia is considered a major trigger.8
It is well accepted that phosphodiesterase-5 inhibitors,
such as sildenafil, are able to improve hemodynamic pa-
rameters and clinical outcome in patients suffering from
PH.5,9,10 The monotherapeutic onsets are still insufficient,
however, especially for pulmonary vessel remodeling and
long-term outcomes; as a result, combined treatment strat-
egies have been adopted, with heterogeneous success.5,11,12
Erythropoietin (Epo) is a pleiotropic cytokine that is up-
regulated during prolonged alveolar hypoxia and causes
increased erythropoiesis.13 Ultimately, Epo improves the
blood’s oxygen-carrying capacity, helping to cope with re-
duced oxygen uptake.14 Of note, Epo also has several non-
erythropoietic functions15 and has been shown to gen-
erate tissue-protective effects in various tissues, such as
skin,16 retina,17 neuronal,18 and heart tissue.19 In addition,
protective effects of Epo in hypoxia-induced PH have been
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indicated in Epo-overexpressing (tg6) mice20 and inmice de-
ficient in the Epo receptor,21 but not in two rat models.22,23
In this study, we tested the hypothesis that combined
treatment with the vasodilator sildenafil and recombinant
human Epo may have superior effects on hypoxia-induced
PH, as compared to treatment with each drug alone. The
primary endpoint of the study was right ventricular pres-
sure (RVP), and secondary endpoints were morphology of
the right heart ventricle and remodeling of the pulmonary
arterial vessels. Using this approach, we were able to dem-
onstrate synergistic effects of the two drugs in combina-
tion, as both the primary and secondary endpoints were
significantly improved upon cotreatment with Epo and
sildenafil, compared to results with single treatments.
MATERIAL AND METHODS
Animals and hypoxic treatment
Wild-type mice (C57BL/6) were randomized, first into
normoxic and hypoxic groups and second to receive sa-
line, Epo, sildenafil, or a combined (Epo and sildenafil)
treatment via subcutaneous injections (n = 6). Humanz re-
combinant Epo (Eprex, Janssen-Cilag) was injected 3 times
per week (500 IU/kg of body weight [BW]), and sildenafil
(a kind gift from Pfizer) was injected daily (10 mg/kg of
BW). The animals were exposed to 3 weeks of either hyp-
oxia (10% oxygen) or normoxia (room air), after which the
animals received the different drugs for additional 2 weeks
under the same environmental conditions. This hypoxic
mouse model for PH is well established, has been de-
scribed by several groups,20,24-26 and is known to result in
PH after 3 weeks of hypoxic exposure.
The normobaric hypoxic chamber was opened for 1 hour
once per week to replace bedding, water bottles, and chow.
Mice of both sexes (10–12 weeks old) were used, and all
experiments were homogeneous regarding sex. In total, 96
animals were used. Experiments were approved by the
Kantonales Veterina¨r Amt in Zurich, Switzerland.
Behavioral observations and spontaneous activity
The animals were exposed to hypoxia for 3 weeks without
treatment, followed by an additional 2 weeks of hypoxia
with treatment. Three days before the end of the treat-
ment period, a video camera was installed to record the
spontaneous activity of each group of animals. The cam-
era was recording from 9 PM to 1 AM, i.e., the most active
phase; later, the behavior and movement of the groups
were compared. An explanatory video is available online.
RVP, blood analysis
The RVP and venous blood gases were measured in
anesthetized mice (2%–2.5% isoflurane in 100% oxygen)
at the end of the 5 weeks of exposure. A small skin in-
cision was made in the neck of the mice, and the right
external jugular vein was isolated to insert a polyethylene
(PE 10) catheter and forward it to the right ventricle of
the heart. In each animal, the blood pressure within the
right ventricle was continuously recorded at a 1-kHz
sampling frequency for at least 30 seconds with a piezo-
electric pressure transducer and the PowerLab system
(ADInstruments). The correct anatomical position of the
catheter tip was controlled by continuously monitoring the
pressure signal curve. After recording, a 100-μL venous
blood sample was drawn from the right ventricle via the
catheter for blood gas analysis (AVL700 Radiometer, Co-
penhagen, Denmark). After blood collection, the animals
were euthanized by cervical dislocation.
Histology
Organs (hearts and lungs) were removed and placed in 4%
formalin for 24 hours before being embedded in paraffin
blocks. Slices 5 μm thick were cut and stained with eosin
and hematoxylin (HE).
Pulmonary vessel wall thickness was measured with
image-analyzing software (MCID 7.0, Image Research,
St. Catharines, Ontario, Canada). Pulmonary vessels near
the alveoli were evaluated, and the diameters of approxi-
mately 20 vessels per slide were determined. From each
animal, 5 slides were evaluated. Simultaneously, we as-
sessed the number of occluded vessels per field (micro-
scope magnification: 40 × 10 = 400-fold). From each HE-
stained slide approximately 20 peribronchial pulmonary
artery vessels were evaluated (microscope magnification:
×400). The degree of occlusion was determined as the ra-
tio between the outer circle and inner (i.e., luminal) circles
of each vessel.
Right ventricular cardiac myocytes displaying central
nuclei were selected for measurement of the cross-
sectional area via the MCID image-analyzing system. For
each heart 4 slides were obtained, and for each slide ap-
proximately 20 cardiomyocytes were measured. Right ven-
tricular hypertrophy was also quantified with the MCID
software. To this end, sections were acquired with a den-
sitometry camera (CoolSNAP cf, Roper Scientific [Pho-
tometrics], Ottobrunn, Germany) after the image size of
the chosen magnification had been calibrated against the
image of a ruler acquired with the identical camera set-
tings. With the drawing tool of the image analyzer, the
left and right ventricles were separated manually with a
thin line in the same way for all sections by a blinded
investigator. Then the areas of the right and the left ven-
tricles could be detected and measured automatically by
the image-analyzing system on the basis of the differ-
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ences in optical density between background and stained
tissue. The results are presented as a ratio, RV/(LV + S),
where RV is right ventricle, LV is left ventricle, and S is
septum. From each animal, 5 slides were evaluated.
Plasma Epo levels
The plasma Epo levels in adult mice were measured by a
specific enzyme-linked immunosorbent assay (ELISA) as-
say (mouse erythropoietin immunoassay; R & D Systems
Europe, Abingdon, UK) according to the manufacturer’s
recommendations. The mean detection limits of Epo were
7.8 and 1,000 pg/mL. All samples were assayed in dupli-
cates and normalized to protein concentration, which was
determined by the bicinchoninic acid (BCA) protein assay
reagent (Pierce Biological, Rockford, IL). Epo was mea-
sured at the end of the 5-week experiment.
Hematocrit
Hematocrit was determined by a routine capillary centri-
fugation, which allows for determination of the volume
fraction of erythrocytes in blood (Haematokrit 24, Het-
tich, Tuttlingen, Germany). Values are expressed as the per-
centage of the volume of erythrocytes to the total blood vol-
ume. Blood for hematocrit measurements was collected at
the end of the experiments.
Determination of ventilation
Ventilation parameters were monitored by whole-body
flow-through plethysmography (Emka Technologies, Paris),
as previously described.27,28 Briefly, mice were placed in a
600-mL chamber continuously supplied with a 0.7–0.8 L/
min airflow controlled by flow restrictors. The ventilation
of mice was recorded twice, before the interventions (ex-
posure to hypoxia/drug treatment) and thereafter accord-
ing to a standardized protocol: at least 5 minutes of record-
ing at rest under normoxic conditions before the oxygen
content within the chamber was gradually decreased
(within 5 minutes) from room air to 10% oxygen, after
which ventilation was recorded for another 10 minutes.
The respiratory data were recorded and analyzed by use
of IOX-2 software (Emka Technologies). The minute ven-
tilation (VE) was calculated as the product of the breath-
ing frequency ( fB) and tidal volume (VT) and normalized
to 100 g BW (mL/min/100 g BW).
Pulmonary edema
Lungs were excised from the animals and separated into
individual lobes. The weight of a lung lobe was deter-
mined before and after heat drying at 70°C for 72 hours.
Results are expressed as a ratio of wet weight to dry
weight.
Cardiotrophin-1 and atrial natriuretic protein (ANP)
Cardiotrophin-1 and ANP were measured in serum by
ELISA kits (ELM-Cardiothrophin-1/EIA-ANP-1, RayBio-
tech, Norcross, GA), according to the manufacturer’s in-
structions.
Data management and statistics
Data are expressed as means  SD of the indicated
number of observations. Statistical comparisons between
groups were performed via one-way ANOVA with a
Newman-Keul’s posttest. For the ventilatory data, the
percentage change in normoxic and hypoxic VE from be-
fore until after 5 weeks of intervention was calculated for
different groups and plotted (Fig. S1, available online).
The percentage changes of VE under normoxic and hyp-
oxic conditions were compared between groups via non-
parametric statistical tests (Kruskal-Wallis rank-sum test,
Mann-Whitney U test). Differences were considered sig-
nificant when P < 0.05.
RESULTS
Observations in hypoxic mice
With decreasing oxygen concentration inside the hypoxic
chamber, mice became progressively lethargic within
1 hour. At 10% O2, the animals were resting motionless
(e.g., paused eating and drinking and stopped grooming),
using their efforts mainly for deep breathing, and the
skin color of their paws and nose turned cyanotic. How-
ever, the animals’ behavior improved over the next hours,
and after 24 hours it was normalized, although the ani-
mals were still cyanotic and showed decreased climbing
activity. At normoxia, the control animals gained approxi-
mately 5%–10% of their BW over the 5 weeks the experi-
ment lasted (Table 1), with the group receiving sildena-
fil gaining significantly more than the other normoxic
groups. The hypoxic animals lost almost 20% of their ini-
tial BW, and this was also the case for the animals receiv-
ing single therapy. For the hypoxic animals receiving the
combination treatment, however, this weight loss was to a
great extent omitted. Furthermore, the heart weight-to-
BW ratio was increased in hypoxic animals compared to
that in the normoxic groups, except for the animals re-
ceiving Epo and sildenafil simultaneously (Table 1).
Epo, hemoglobin, and hematocrit
Endogenous mouse Epo measured at the end of the
experiment was elevated approximately 4-fold in plasma
from hypoxic control animals, compared to that in nor-
moxic mice (Table 2). As expected, hemoglobin levels were
elevated after hypoxic exposure, and this was slightly, but sig-
nificantly, attenuated by sildenafil as well as by the combi-
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nation treatment. In addition, hematocrit was increased
in response to hypoxia but was unchanged with treatments,
except for a small increase in the Epo-treated group. For all
groups, there was a clear and significant sex difference (data
not shown), with the hematological values for the female
mice being approximately 25% lower than those for their
male counterparts.
Venous blood analysis
Most of the measured plasma electrolytes were altered in
response to hypoxia and returned to baseline with the
combination treatment (Table S1, available online). Hyp-
oxia caused a reduction in pH, which returned to normal
values with the combination treatment. Lactate levels were
increased under hypoxia; this was gradually attenuated by
the single treatments, and levels returned to baseline with
the combination treatment. With regard to base excess (BE)
and bicarbonate (HCO3 ), no significant variations were ob-
served.
Ventilation
The acclimatization to chronic hypoxia involved an ele-
vation of ventilation (Fig. S1a). The percentage change
in hypoxic VE (before vs. after 5 weeks of intervention;
Fig. S1b) was increased in the Epo-treated animals, as
compared to the hypoxic control group and the sildenafil
group. The increase observed for the cotreated group
was significant only when compared to that of the sil-
denafil group.
Hemodynamic measurements
Measurements of the RVP revealed that hypoxic animals
had developed a severe increase in RVP, approximately
65%, after being exposed to hypoxia for 5 weeks (Fig. 1).
This increase was reduced significantly by treatment
with Epo and even more so with sildenafil. The combi-
nation treatment attenuated the pressure even further,
thereby returning it almost, though not significantly, to
baseline normoxic values.
Table 2. Erythropoietin (Epo) and hematocrit
21% O2 10% O2
Control Epo Sildenafil E & S Control Epo Sildenafil
Epo(m), mU/mL 7.2 ± 2.1 9.2 ± 6.8 7.1 ± 4.4 12.8 ± 10.1 32.1 ± 19.8 30.1 ± 13.8 22.9 ± 18.5
Hemoglobin, g/dL 11.6 ± 0.9#§ 11.3 ± 0.7#§ 10.3 ± 0.6#§ 11.0 ± 0.7#§ 18.9 ± 2.6#§ 19.5 ± 1.2#§ 16.7 ± 3.0*
Hematocrit, % 39.7 ± 6.7*#§ 58.6 ± 4.2 39.4 ± 1.9*#§ 54.0 ± 2.3 52.2 ± 6.4 66.5 ± 8.8* 56.9 ± 8.3
Note: All parameters were measured in plasma. For hemoglobin, all normoxic values were significantly different from all hyp-
oxic values (n = 6–12). Boldface indicates values that are significantly altered (n = 6–12). Epo(m): endogenous mouse Epo (n = 3).
E & S: combined Epo and sildenafil.
* P < 0.05 compared to hypoxic control.
# P < 0.05 compared to 10% O2 with E & S.
§ P < 0.05 compared to 10% O2 with sildenafil.
Table 1. Gained body weight (BW) and BW to heart weight (HW) ratio
21% O2 10% O2
Control Epo Sildenafil E & S Control Epo Sildenafil E & S
ΔBW, % 5.8 ± 3.3 7.6 ± 5.3 13.4 ± 1.8 8.8 ± 4.2 −18.9 ± 7.6*# −16.0 ± 5.5*# −18.4 ± 4.6*# −5.4 ± 8.1#
HW ∶BW 5.1 ± 0.6 5.3 ± 0.8 4.8 ± 0.6 4.8 ± 0.3 6.3 ± 0.9*# 6.5 ± 0.7 *# 6.1 ± 0.5# 5.5 ± 0.4
Note: Boldface indicates values that are significantly altered (n = 6–12). Epo: erythropoietin; E & S: combined Epo and sildenafil.
* P < 0.05 compared to 10% O2 with E & S.
# P < 0.05 compared to 21% O2, all groups.
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Pulmonary vascular remodeling
The histological stainings (Fig. 2A) clearly illustrate the
increased arterial vessel wall diameters in lungs from
animals exposed to hypoxia and also the modulating ef-
fect of different drug treatments. Pulmonary vessel wall
thickness was evaluated (Fig. 2B). In normoxic animals
(control and treatment groups), the vessel wall diameter
was approximately 0.7  0.07 μm. This rose to 1.86  0.11
μm in the hypoxic control group but was gradually reduced
with both Epo and sildenafil treatment and was reduced
considerably more with the combination therapy. The per-
centage of occluded vessels (Fig. 2C ) in lungs of normoxic
animals was approximately 8 times that in the untreated
hypoxic animals. Administering Epo, sildenafil, or both
drugs simultaneously gradually lowered the number of oc-
cluded vessels.
Pulmonary edema
Pulmonary edema was estimated by the wet-to-dry lung
weight ratio (Fig. 3). Under normoxic conditions there
was no impact of the treatments on the intact lung. Hyp-
oxic exposure for 5 weeks increased the wet-to-dry weight
ratio of the untreated lung by about 28%. Edema forma-
tion was, however, reduced by both single treatments and
returned to normoxic control levels under the combina-
tion of sildenafil and Epo.
Right ventricular hypertrophy
Right ventricular hypertrophy (Fig. 4A) was assessed by
histology. For the normoxic groups, control versus treat-
ment, no change was detected in the RV/(LV + S) ratio,
whereas an apparent enlargement of the RV after 5 weeks
of hypoxia was observed (Fig. 4B). This enlargement was
attenuated with both single treatments but significantly
more with the combination of the two drugs.
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Figure 1. Hemodynamic measurements in anesthetized mice.
Right ventricle pressure of different groups after 5 weeks of
chronic 10% hypoxic exposure with or without treatment, com-
pared to that of normoxic, untreated control mice (open bar);
treatment groups, from left to right: hypoxia only, hypoxia and
erythropoietin (Epo) alone, hypoxia and sildenafil alone, and hyp-
oxia and combination of Epo and sildenafil (n = 5). An asterisk
indicates P < 0.05 versus hypoxic control, and a pound sign in-
dicates P < 0.05 versus hypoxia and cotreatment with Epo and
sildenafil.
* * * *
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Figure 2. A, Representative images
of small pulmonary arteries (50–
200 μm) stained with eosin and
hematoxylin (arrows), showing re-
duced hypoxia-induced remodeling
of intimal and medial vessel layer
upon treatment: a, normoxic control;
b, hypoxic control; c, hypoxia and
erythropoietin (Epo) alone; d, hypoxia
and sildenafil alone; e, hypoxia and
cotreatment with Epo and sildenafil.
B, Pulmonary vessel wall thickness
(n = 8); open bars for normoxic mice,
filled bars for hypoxic mice. C,
Pulmonary lung vessel occlusion
(n = 8). Treatment groups in B and
C are indicated below the bars, as
in Figure 1. An asterisk indicates
P < 0.05 versus hypoxic control, and
a pound sign indicates P < 0.05
versus hypoxia and cotreatment with
Epo and sildenafil.
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The cross-sectional areas of the right ventricular car-
diomyocytes were also determined (Fig. 4C ), and again
no change was observed in the normoxic groups, whereas
almost a doubling was detected after hypoxic exposure.
Epo or sildenafil alone could diminish the hypoxia-
induced enlargement, and a further reduction was observed
when both drugs were administered simultaneously.
Cardiotrophin-1 and ANP
The cytokines cardiotrophin-1 and ANP were measured
in plasma obtained from all mouse groups at the end of
the experiment (Table 3). Plasma levels of both factors
were unaltered during normoxia but highly augmented
under hypoxia. This augmentation was lowered with both
single treatments and was lowered significantly more
when Epo and sildenafil were given in combination.
DISCUSSION
In this study, we found convincing evidence for addi-
tive effects when combining the two drugs sildenafil and
Epo for the treatment of hypoxia-induced PH in a mouse
model. All endpoints improved after 2 weeks of single
* * *
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Figure 3. Quantification of pulmonary edema formation via
estimation of lung wet-to-dry weight ratio, showing increased
edema formation in mice chronically exposed to 10% oxygen
for 5 weeks when compared to normoxic mice (open bars) with
or without treatment and hypoxic mice with treatment (n = 3).
Treatment groups are indicated below the bars, as in Figure 1.
Epo: erythropoietin. An asterisk indicates P < 0.05 versus hyp-
oxic control, and a pound sign indicates P < 0.05 versus hyp-
oxia and cotreatment with Epo and sildenafil.
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Figure 4. Different treatments prevent ventricular remodeling of the heart. A, Representative images of cross-sectional slices of the
heart (horizontal cut through the mouse heart at ventricular level), showing reduced hypoxia-induced hypertrophic transformation
of the right ventricle (RV) due to the treatments; LV = left ventricle: a, normoxic control; b, hypoxic control; c, hypoxia and
erythropoietin (Epo) alone; d, hypoxia and sildenafil alone; e, hypoxia and cotreatment with Epo and sildenafil. B, Quantification of
right ventricular hypertrophy via estimation of the ratio of RV area to (LV + septum) area (n = 4–6). C, Hypoxia-induced hypertro-
phy of the cardiomyocytes was affected significantly by the treatments (n = 4–6). Treatment groups in B and C are indicated below
the bars, as in Figure 1. An asterisk indicates P < 0.05 vs. hypoxic control, and a pound sign indicates P < 0.05 vs. hypoxia and
cotreatment with Epo and sildenafil.
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treatments and to an even higher extent by simultaneous
application of both drugs.
Observations in hypoxic mice
Mice recovered within the first 24 hours of hypoxic expo-
sure, so that they restarted eating, drinking, and inter-
acting socially. Clear differences were observed, however,
in overall movement and the intensity thereof. In gen-
eral, untreated control animals appeared fatigued and
moved in the hypoxic chamber only in order to acquire
food or water. In the groups receiving treatment, how-
ever, an apparent increase (not quantified) in the ability to
move and interact was observed, and this was especially
clear for the group receiving combined treatment (see
the video available online). On the basis of these observa-
tions, our initial conclusion was that treatment with sil-
denafil alone improved the overall health status and that
this effect was augmented in combination with Epo. This
was further supported by the fact that hypoxia-induced
weight loss was alleviated by the combination treatment.
Effects on blood parameters
Hematocrit, as expected, increased with hypoxic expo-
sure. Endogenous Epo also exhibited a tendency for a
hypoxia-induced augmentation. Sildenafil treatment, alone
as well as in combination with exogenous human Epo, was
able to attenuate this increase. We suggest that the rea-
son for this was an overall improved ventilation-perfusion
match, leading to better systemic and tissue oxygenation
that resulted in reduced endogenous Epo release and ul-
timately in lowering of hemoglobin and hematocrit levels.
Lactate levels were higher under hypoxia, because im-
paired cellular respiration leads to a switch to anaerobic
glucose utilization, thereby increasing the production of
lactate.29 This phenomenon is known as lactic acidosis
and will also contribute to a lower pH value. Indeed, we did
observe that pH and lactate levels mirrored each other, with
pH being lower in hypoxic control animals and lactate
higher. Both values normalized in all hypoxic groups
rethe pH level was even further increased. The rather
low pH value in normoxic animals is most likely due to
isoflurane-induced respiratory acidosis.30
The concentration of several blood electrolytes was al-
tered in hypoxic animals, and with treatments, especially
the cotreatment, these values returned toward baseline
levels. Electrolytes play a crucial part in maintaining ho-
meostasis within the body. They are critical for the gener-
ation of energy, maintenance of cell wall stability, con-
traction of muscles, movement of water and fluids, and
numerous other functions. Thus, preserving the electro-
lyte balance is of utmost importance.
Effects on ventilation
The VE of mice at rest was generally increased after chronic
hypoxia for 5 weeks, a well-known mechanism to com-
pensate for lower oxygen levels termed “ventilatory accli-
matization to hypoxia.”31,32 The percentage change of hyp-
oxic VE (before vs. after 5 weeks of hypoxia + treatment)
was, in contrast to that in normoxic conditions, signifi-
cantly altered within different groups. Of note, those ani-
mals receiving Epo (either alone or in combination with
sildenafil) showed a significant increase in VE under hyp-
oxic conditions, as compared to the untreated hypoxic con-
trol group and the sildenafil single-treatment group. De-
spite the fact that endogenous Epo is released under hypoxic
conditions,33,34 this finding is in agreement with already
published data demonstrating that exogenously applied Epo
affects the peripheral cardiorespiratory network through
the carotid bodies, by increasing hypoxic VE to ultimately
improve oxygenation during hypoxia.27 The observed
stimulating effect of Epo treatment on VE was more evi-
dent when compared to results in the sildenafil single-
treatment group, suggesting that Epo and sildenafil have
counterbalancing effects on ventilation in hypoxia.
Table 3. Plasma values for cardiotrophin-1 (CT-1) and atrial natriuretic protein (ANP)
21% O2 10% O2
Control Epo Sildenafil E & S Control Epo Sildenafil E & S
CT-1, ng/mL 1.3 ± 0.3 1.5 ± 0.2 1.4 ± 0.2 1.6 ± 0.1 9.4 ± 0.7# 6.1 ± 0.6*# 5.9 ± 0.5 *# 4.2 ± 0.6*
ANP, ng/mL 0.62 ± 0.08 0.74 ± 0.11 0.72 ± 0.13 0.72 ± 0.05 3.85 ± 0.45# 2.67 ± 0.17*# 2.56 ± 0.16*# 1.77 ± 0.21*
Note: Bold numbers represent values that are significantly altered. All normoxic values were significantly different from all
hypoxic values (n = 5). Epo: erythropoietin; E & S: combined Epo and sildenafil.
* P < 0.05 compared to hypoxic control.
# P < 0.05 compared to 10% O2 with E & S.
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Effects on RVP
RVP is an indirect measure, but it represents a good
estimate of the pulmonary artery pressure.35 RVP was
our primary endpoint, and as we hypothesized, the ani-
mals developed PH upon hypoxic exposure. RVP could
be reduced by both Epo and, to a larger extent, sildenafil.
Furthermore, we observed an additive effect of the two
drugs when applied in combination. After only 2 weeks
of treatment, while the animals were still exposed to hyp-
oxia, RVP returned almost to normoxic baseline levels
when the two drugs were administered in combination.
Effects on pulmonary vessels and lung
edema formation
The remodeling of the pulmonary arterial vessels was
assessed by wall thickness as well as by counting the
number of occluded vessels. For both parameters, an in-
crease was observed after 5 weeks of hypoxia. Either drug
alone could diminish these alterations of the pulmonary
vasculature, but the effect was significantly higher with
the combination treatment. This was also the case for
pulmonary edema formation, indicated by an increase in
the wet-to-dry lung weight ratio upon hypoxia in the un-
treated control animals that was nearly abolished by the
treatments.
Effects on RV morphology and parameters
of heart function
RV hypertrophy was verified by histology, demonstrating
attenuation in the hypoxia-induced increases in the RV/
(LV + S) ratio and cardiomyocyte cross-sectional area with
both single-drug treatments and a significantly higher ef-
fect with the combination treatment. To further evalu-
ate heart function, we measured the plasma values of
cardiotrophin-1 and ANP. The first cytokine is a cardiac
hypertrophic factor associated with growth and dysfunc-
tion of the heart,36 and the latter is a hormone released
from the atria of the heart in response to high blood pres-
sure that acts to reduce the water, sodium, and adipose
loads on the circulatory system, thereby reducing blood
pressure.37 The levels of both factors were increased in
plasma from hypoxic untreated animals and attenuated
by each single treatment and significantly more by the
cotreatment, supporting the finding of a reduction in RV
hypertrophy and RVP.
Accordingly, we conclude that both sildenafil and Epo
have beneficial effects on improving the pathophysiologi-
cal changes induced by prolonged exposure to hypoxia
and subsequent development of PH. Sildenafil is already
approved for the treatment of PH, and in a randomized,
double-blind, placebo-controlled crossover study, silden-
afil was found to improve World Health Organization
functional class and hemodynamics in patients suffering
from PH.38 So as a pulmonary vasodilator, sildenafil is
an established therapeutic option, albeit one with limited
effects. The effects of Epo in the setting of PH is less
investigated, but using tg6 mice that constitutively over-
express human Epo in an oxygen-independent manner,
Weissmann and coworkers20 demonstrated that these
transgenic mice display reduced vascular remodeling
and/or media thickness, as well as blunted vascular re-
sistance and vasoconstrictor response, both under con-
trol conditions and in a model of chronic normobaric
hypoxia. This is in support of our results; what distin-
guishes our findings from theirs is that we used exoge-
nous and not endogenously overproduced Epo and that
we initiated the treatment only after the onset of PH. We
also kept the hematocrit at a more physiological level,
thereby avoiding possible side effects due to the excessive
erythrocytosis occurring in tg6 animals. Other groups
have reported, for instance, a blunted response to U46619
in isolated perfused lungs of tg6 animals39 as well as in
Epo-treated rats.40 In the monocrotaline rat model of PH,
both negative22 and positive41 effects of Epo have been
reported, whereas in Hilltop and Madison rats exposed to
hypoxia, no effects were observed.23 Finally, an Epo recep-
tor knockout model revealed a higher pulmonary vascular
response after hypoxic exposure.21 The effects of Epo in
the setting of hypoxia and PH are therefore not clear, and
we thus propose that the results from our study reveal an
additive effect of combining sildenafil and Epo and that
these findings can provide the basis for further investi-
gations and the development of novel therapeutic strate-
gies not only for the treatment of PH but also in other
cardiovascular pathologies.
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